Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Cash flows from operating activities:
Net loss	$ (5,160,966)	$ (1,102,291)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense	630,659	453,551
Change in fair value of warrants		(2,600,000)
Depreciation and amortization	161,461	74,994
Changes in operating assets and liabilities:
Accounts receivable	(388,379)	962,050
Prepaid expenses and other current assets	46,907	45,729
Accounts payable and accrued expenses	(271,806)	(1,347,191)
Deferred contract revenue	(4,336,036)	(2,826,920)
Other	(36,774)	42,582
Net cash used in operating activities	(9,354,934)	(6,297,496)
Cash flows from investing activities:
Equipment and leasehold improvement expenditures	(37,734)	(154,751)
Patent expenditures	(272,196)	(149,888)
Net cash used in investing activities	(309,930)	(304,639)
Cash flows from financing activities:
Proceeds from sale of common stock and warrants, net		8,211,946
Proceeds from options and warrants exercised	3,289
Payment for restricted stock tax liability on net settlement	(44,833)
Net cash (used in) provided by financing activities	(41,544)	8,211,946
Net (decrease) increase in cash and cash equivalents	(9,706,408)	1,609,811
Cash and cash equivalents at beginning of period	24,621,083	14,410,630
Cash and cash equivalents at end of period	14,914,675	16,020,441
Cash paid during the period for:
Income taxes	1,600	1,600
Supplemental disclosure of non-cash investing and financing activities:
Change in fair value of warrant liability		$ (2,600,000)